Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Obesity

Interventions: Drug: Placebo
Drug: BI 10773

First Posted Date: 2011-03-01

Last Posted Date: 2014-06-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 566

Registration Number: NCT01306214

Locations: 🇺🇸
1245.49.10019 Boehringer Ingelheim Investigational Site, Westlake Village, California, United States
🇺🇸
1245.49.10007 Boehringer Ingelheim Investigational Site, Fargo, North Dakota, United States
🇺🇸
1245.49.10015 Boehringer Ingelheim Investigational Site, Evansville, Indiana, United States

and more 100 locations

Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran etexilate
Drug: Dabigatran etexilate plus dronedarone

First Posted Date: 2011-03-01

Last Posted Date: 2014-06-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT01306162

Locations: 🇩🇪
1160.112.1 Boehringer Ingelheim Investigational Site, Ulm, Germany

Drug Interaction Study of Digoxin and BI 10773

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Digoxin plus BI 10773
Drug: Digoxin

First Posted Date: 2011-03-01

Last Posted Date: 2014-06-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT01306175

Locations: 🇩🇪
1245.40.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Drug-drug Interaction of Empagliflozin (BI 10773) and Simvastatin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773
Drug: simvastatin

First Posted Date: 2011-02-25

Last Posted Date: 2014-07-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT01304329

Locations: 🇩🇪
1245.63.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Aggrenox and omeprazole
Drug: Omeprazole alone
Drug: Aggrenox alone

First Posted Date: 2011-02-24

Last Posted Date: 2013-12-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT01303445

Locations: 🇺🇸
9.197.001 Boehringer Ingelheim Investigational Site, Tempe, Arizona, United States

Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773
Drug: Gemfibrozil

First Posted Date: 2011-02-23

Last Posted Date: 2014-06-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT01301742

Locations: 🇩🇪
1245.58.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib

Phase 1

Completed

Conditions: Healthy
Liver Diseases

Interventions: Drug: Afatinib

First Posted Date: 2011-02-17

Last Posted Date: 2013-12-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 35

Registration Number: NCT01298063

Locations: 🇩🇪
1200.86.1 Boehringer Ingelheim Investigational Site, Kiel, Germany

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: BI201335
Drug: Placebo
Drug: PegIFN/RBV

First Posted Date: 2011-02-16

Last Posted Date: 2015-09-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 658

Registration Number: NCT01297270

Locations: 🇺🇸
1220.47.0057 Boehringer Ingelheim Investigational Site, Bradenton, Florida, United States
🇺🇸
1220.47.0078 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States
🇺🇸
1220.47.0086 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States

and more 103 locations

BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)

Phase 1

Completed

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: BI 836826

First Posted Date: 2011-02-16

Last Posted Date: 2020-08-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 37

Registration Number: NCT01296932

Locations: 🇧🇪
UNIV UZ Gent, Gent, Belgium
🇫🇷
CTR Investigation Clinique, onco, Montpellier, Montpellier Cedex 5, France
🇫🇷
INS Universitaire du Cancer, Toulouse, France

and more 7 locations

Single Rising Dose Study of BI 135585 XX in Health Asian Male Volunteers.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 135585 XX
Drug: Matching placebo

First Posted Date: 2011-02-08

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT01291732

Locations: 🇰🇷
1283.5.82001 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy